Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31239069 | 0.86 | TSHR (0.56) | TSHRCYP3A4KAT2BALDH1A1CYP1A2 | |
| SCHEMBL4387980 | 0.86 | TSHR (0.56) | TSHRCYP3A4KAT2BALDH1A1CYP1A2 | |
| SCHEMBL7193090 | 0.82 | TSHR (0.64) | TSHRCYP3A4KAT2BALDH1A1CYP1A2 | |
| SCHEMBL27599498 | 0.80 | TSHR (0.62) | TSHRCYP3A4KAT2BALDH1A1LMNA | |
| SCHEMBL405343 | 0.79 | ACHE (0.40) | TSHRCYP3A4ALDH1A1ACHEMEN1 | |
| SCHEMBL405093 | 0.79 | TSHR (0.55) | TSHRALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL4647436 | 0.79 | ATM (0.55) | TSHRALDH1A1MAPTKMT2A | |
| SCHEMBL3118876 | 0.79 | TSHR (0.51) | TSHRCYP3A4KAT2BALDH1A1CYP1A2 | |
| SCHEMBL16094926 | 0.79 | ALDH1A1 (0.46) | CYP3A4ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL68019 | 0.79 | TSHR (0.60) | TSHRCYP3A4KAT2BALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180237-A1 | METHOD AND COMPOUND | ATDBio Limited (GB) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023099471-A1 | METHOD FOR PRODUCING POLYNUCLEOTIDES | ATDBio Limited (GB) | 2023-06-08 | — | — | WO | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1866645-A2 | ELECTROCHEMICAL ASSAY | Inverness Medical Switzerland GmbH (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103450-A2 | ELECTROCHEMICAL ASSAY | INVERNESS MEDICAL SWITZERLAND GMBH (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TSHR 82/4885CYP3A4 2376/4885KAT2B 979/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TSHR 82/4885CYP3A4 2376/4885KAT2B 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.